HomeAI · summaries
Storia in 3 fonti
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge…
- ·
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant…
- ·
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…
- ·
statnews.com
A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
- ·
endpoints.news
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries